Sunshine Biopharma Inc. (SBFM) stock

SBFMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFMW

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3099% below fair value

$2.84+0.09 (+3.27%)

Close on Nov 12, 2026Market cap $790.42KP/E –Yield –

Sunshine Biopharma statistics

74 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 12, 2026

Valuation ratiosIndustry

Market Cap: $790.42K; $280.48M
Enterprise Value: -$13.83M; $148.62M
PS Ratio: 0.02; 3.60
PB Ratio: 0.03; 2.05
P/TBV Ratio: 0.03; 2.29

Enterprise valuationIndustry

EV / Sales: -0.39; 2.60

Share statisticsIndustry

Shares Outstanding: 278,317; 58M
Shares Change (YoY): 2511.3%; 10.9%
Shares Change (QoQ): -88.3%; 0.51%
Float: 210,016; 49M
Shares Held by Insiders: 24.5%; 12.1%
Shares Held by Institutions: 28.9%; 56.4%

Short sellingIndustry

Short Interest: 176,303; –
Short Interest Change: -79.0%; -0.76%
Days to Cover: 1.03; 5.13

Stock price statisticsIndustry

52-Week High: $464.00; –
52-Week Low: $0.20; –
20-Day Moving Average: $2.77; –
50-Day Moving Average: $7.28; –
200-Day Moving Average: $90.34; –
Average True Range (14): $1.52; –
Price Change (1 Week): 1.79%; 1.51%
Price Change (1 Month): 1068.7%; -2.35%
Price Change (3 Months): -87.7%; -21.1%
Price Change (6 Months): -97.0%; -22.6%
Price Change (YTD): -98.8%; -22.6%
Price Change (1 Year): -99.2%; -20.7%
Price Change (3 Years): -94.3%; -27.4%
Price Change (5 Years): -76.3%; -77.3%
Price Change (10 Years): 42.0%; -62.7%
Average Volume (10 Days): 60,778; –
Average Volume (20 Days): 222,958; –
Average Volume (90 Days): 473,908; –
Relative Volume: 0.11; 0.79
Relative Strength Index (14): 45.8; 44.7
Volatility (1 Year): 7328.3%; 80.4%

MarginsIndustry

Gross Margin: 30.4%; 53.0%
Operating Margin: -17.2%; -38.7%
Pretax Margin: -16.5%; -11.8%
Profit Margin: -17.5%; -32.0%
EBITDA Margin: -16.3%; -27.7%

Returns on capitalIndustry

Return on Equity (ROE): -23.4%; -51.2%
Return on Assets (ROA): -18.9%; -40.6%
Return on Invested Capital (ROIC): -33.3%; -32.9%
Return on Capital Employed (ROCE): -20.9%; -38.0%

Financial positionIndustry

Current Ratio: 6.47; 3.30
Quick Ratio: 3.86; 2.42

GrowthIndustry

Revenue Growth (YoY): -5.23%; 7.01%
Revenue Growth (3Y CAGR): 102.9%; 2.25%
Revenue Growth (5Y CAGR): 247.7%; 6.41%

EfficiencyIndustry

Asset Turnover: 1.08; 0.40
Inventory Turnover: 1.92; 2.73
Revenue Per Employee: $707.44K; $429.29K
Profits Per Employee: -$123.46K; -$683.67K
Employee Count: 50; 75

Income statement (TTM)Industry

Revenue: $35.37M; $66.37M
Gross Profit: $10.74M; $116.10M
Operating Income: -$6.09M; -$20.99M
Pretax Income: -$5.83M; -$13.23M
Net Income: -$6.17M; -$21.61M
EBITDA: -$5.76M; -$16.85M
EPS (Diluted): -$145.30; -$0.75

Balance sheetIndustry

Cash & Short-Term Investments: $14.62M; $67.63M
Net Cash (Debt): $14.62M; $17.46M
Net Cash Per Share: $52.52; $0.72
Equity (Book Value): $28.64M; $53.27M
Book Value Per Share: $102.89; $1.50
Tangible Book Value: $26.74M; $26.82M
Working Capital: $26.21M; $79.47M

Cash flow (TTM)Industry

Operating Cash Flow: -$5.99M; -$12.27M

Dividends and yieldsIndustry

Earnings Yield: -781.0%; -20.8%

Taxes and interestIndustry

Income Tax: $344.84K; $74.00K

Scores and fair valueIndustry

Altman Z-Score: -1.80; 0.30
Piotroski F-Score: 4; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	SBFM	S&P 500	Difference	SBFM per year	S&P 500 per year
1 month	+840.4%	-2.7%	+843.1 pts
3 months	-88.3%	-1.7%	−86.5 pts
Year to date	-98.8%	+11.9%	−110.7 pts
1 year	-99.2%	+12.0%	−111.2 pts
3 years	-95.1%	+78.2%	−173.3 pts	-63.4%	+21.2%
5 years	-76.3%	+73.2%	−149.6 pts	-25.0%	+11.6%
10 years	+42.0%	+309.6%	−267.6 pts	+3.6%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

0M SBFM shares were sold short on Oct 30, 2026, down 79.0% from the previous report. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 55.4% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	176,303	-79.0%	170,382	1.0
Oct 15, 2026	840,899	+539.6%	28,786,521	1.0
Sep 30, 2026	131,478	+461.6%	161,724	1.0
Sep 15, 2026	23,410	-73.1%	121,189	1.0
Aug 31, 2026	86,934	+17.6%	1,102,851	1.0
Aug 14, 2026	73,942	-41.5%	1,475,299	1.0
Jul 31, 2026	126,399	+102.4%	153,914	1.0
Jul 15, 2026	62,455	-45.0%	48,069	1.3
Jun 30, 2026	113,463	-35.0%	128,062	1.0
Jun 15, 2026	174,691	-87.9%	1,382,111	1.0
May 29, 2026	1,443,031	+190.9%	89,699,299	1.0
May 15, 2026	496,125	+376.4%	321,722	1.5

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Sunshine Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-200 reverse split on Aug 13, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SBFM.

Compare: SBFM vs MCUJF · SBFM vs BHST · SBFM vs LXRX · SBFM vs JAGX · SBFM vs AYTU

Revenue growth-5.2% · median -13.3%

Gross margin30.4% · median 82.3%

Operating margin-17.2% · median -93.1%

Net margin-17.5% · median -93.3%

Company	Revenue	Growth
AYTU	$57.57M	-13.3%
LXRX	$38.54M	-45.6%
SBFM	$35.37M	-5.2%
JAGX	$27.82M	+135.5%
MCUJF	–	–
BHST	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 50
Auditor: Bush & Associates CPA LLC
SEC CIK: 1402328

Advertisement
300 × 250

See a number that looks wrong?